Loxo Oncology, Inc.
Clinical trials sponsored by Loxo Oncology, Inc., explained in plain language.
-
New targeted drug pirtobrutinib takes on ibrutinib in major blood cancer trial
Disease control Recruiting nowThis study compares a newer targeted drug, pirtobrutinib, to an older one, ibrutinib, in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 662 participants will be enrolled, some who have had prior treatment and some who have not. The goal …
Phase: PHASE3 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated May 18, 2026 12:04 UTC
-
New hope for blood cancer patients: experimental drug pirtobrutinib enters phase 2 trial
Disease control Recruiting nowThis study tests three different doses of an experimental drug called pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer came back or didn't respond to a previous type of targeted therapy (a BTK inhibitor). The goal is…
Phase: PHASE2 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated May 14, 2026 12:03 UTC